Global pharmaceutical companies, facing resistance to drug pricing from various European capitals, are deploying a recently successful "old playbook" from the UK: pressuring policymakers by threatening to withdraw investments and expansion plans. The latest target is Germany, where legislation aimed at tightening pharmaceutical spending is currently under debate. This follows the industry's victory in the UK, where the government agreed to increase drug spending, part of a broader agreement to avoid US-imposed tariffs.
Pfizer (PFE.US) sent a letter to the German Chancellor last week, warning that its investments in Germany are at risk due to the country's current drug pricing policies. AstraZeneca PLC (AZN.US) cautioned that it might not launch new drugs in Germany if the proposed changes are implemented. Earlier in June, Eli Lilly (LLY.US) announced it would halve a planned €2.3 billion (approximately $2.7 billion) investment. Even Germany-based Boehringer Ingelheim stated it would cancel a €900 million expansion plan. Both companies attributed these decisions to the proposed legislation.
Pressure Yields Results in the UK
The UK government's eventual capitulation to industry pressure has brought delight to the sector. A representative from the UK patient organization Just Treatment noted, "They are happy to see this kind of compromise replicated in other countries." The German Health Ministry stated this week that no final decisions have been made and declined to comment further on parliamentary deliberations.
Germany Feels the Strain
Critics argue the UK bowed to pressure from drugmakers. However, the UK government maintains that its April agreement with Washington secured tariff-free access to the US market while also fostering a more innovation-friendly environment for pharmaceutical companies, thereby supporting high-skilled jobs. The pressure on Germany is now beginning to show tangible effects. A government source revealed on Monday that Germany will drop parts of its plan opposed by the industry, such as shifting from a variable to a fixed discount mechanism, in response to market concerns about investment deterrence due to uncertainty. While this reduces unpredictability, industry insiders say it does not address deeper concerns about Germany's overall pricing environment. The proposed bill will face parliamentary debate in the coming months and may still be amended.
Industry Reaction and Broader Context
Industry figures view the UK deal positively, not only for its changes to the system for valuing and paying for new drugs but also for its commitments to innovation and patient access. ING healthcare analyst Diederik Stadig suggested that, compared to the more premeditated strategy used in the UK, actions in Germany are more reactive. However, he agreed the two cases are very similar. "The German government proposed a reform, and the industry responded by saying it impacts their return on investment," he stated. Stadig noted that factors like US tariffs, US pricing policies, China's rise, and the high-profit US market are making Europe less attractive. "The pharmaceutical industry is making Europe acutely aware of this," he added.
Wider European Tensions Over Pricing
Germany's proposed legislation to curb soaring costs in its statutory health insurance system places it at the center of a broader struggle between drugmakers and European governments that began months ago. In France, the National Health Authority accused companies in April of using "coercive pressure," including threats to withdraw drugs, to influence clinical assessments. The Dutch biotech lobby group HollandBio stated companies are becoming more cautious with reimbursement applications, risking the Netherlands falling further down the priority list for drug launches. Tensions are further heightened by the impact of former US President Donald Trump's "Most Favored Nation" drug pricing policy, which aimed to link US drug prices to lower prices in other regions, including Europe. Major drugmakers have struck deals with the White House to lower costs in exchange for tariff exemptions, increasing pressure to raise prices elsewhere.
Critics Voice Concern
Some critics view Germany's partial retreat as a worrying sign of the pharmaceutical industry's leverage. However, they also point out that European nations hold significant sway as important markets, even if less profitable than the US. An analyst from the healthcare think tank Nuffield Trust stated, "The US is not the only market in the world," but added that the UK-US pricing agreement serves as a warning for Europe. "The frustrating reality is that this 'UK playbook' means health systems will spend more for less health benefit for their populations," she concluded.
Comments